Literature DB >> 17263184

Human experimental pain models in drug development: translational pain research.

Lars Arendt-Nielsen1, Michele Curatolo, Asbjørn Drewes.   

Abstract

Human experimental pain models require standardized stimulation and quantitative assessment of the evoked responses. This approach can be applied to healthy volunteers and pain patients before and after pharmacological interventions. Standardized stimuli of different modalities (ie, mechanical, chemical, thermal or electrical) can be applied to the skin, muscles and viscera for a differentiated and comprehensive assessment of various pain pathways and mechanisms. Using a multi-modal, multi-tissue approach, new and existing analgesic drugs can be profiled by their modulation of specific biomarkers. It has been shown that biomarkers, for example, those related to the central integration of repetitive nociceptive stimuli, can predict efficacy of a given drug in neuropathic pain conditions. Human experimental pain models can bridge animal and clinical pain research, and act as translational research providing new possibilities for designing successful clinical trials. Proof-of-concept studies provide cheap, fast and reliable information on dose-efficacy relationships and how pain sensed in the skin, muscles and viscera are inhibited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263184

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  26 in total

1.  Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain.

Authors:  T Andresen; C Staahl; A Oksche; H Mansikka; L Arendt-Nielsen; A M Drewes
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.

Authors:  Anne E Olesen; Richard Upton; David J R Foster; Camilla Staahl; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

3.  Clinical Interpretation of Quantitative Sensory Testing as a Measure of Pain Sensitivity in Patients With Sickle Cell Disease.

Authors:  Amanda M Brandow; Julie A Panepinto
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

Review 4.  Unravelling the mystery of capsaicin: a tool to understand and treat pain.

Authors:  Jessica O'Neill; Christina Brock; Anne Estrup Olesen; Trine Andresen; Matias Nilsson; Anthony H Dickenson
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

5.  Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis.

Authors:  Martin J De Vita; Dezarie Moskal; Stephen A Maisto; Emily B Ansell
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

6.  Intradermal capsaicin as a neuropathic pain model in patients with unilateral sciatica.

Authors:  Verna Aykanat; Melanie Gentgall; Nancy Briggs; Desmond Williams; Sharon Yap; Paul Rolan
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

7.  Recent advances in the treatment of pain.

Authors:  Mellar P Davis
Journal:  F1000 Med Rep       Date:  2010-08-19

Review 8.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 9.  Use of sensory methods for detecting target engagement in clinical trials of new analgesics.

Authors:  Boris A Chizh; Christine N Sang
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Validation, reproducibility and safety of trans dermal electrical stimulation in chronic pain patients and healthy volunteers.

Authors:  Remigiusz Lecybyl; Juan Acosta; Joydeep Ghoshdastidar; Kinga Stringfellow; Magdi Hanna
Journal:  BMC Neurol       Date:  2010-01-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.